Your browser doesn't support javascript.
loading
SARS-CoV-2: Evolution and Emergence of New Viral Variants.
Flores-Vega, Verónica Roxana; Monroy-Molina, Jessica Viridiana; Jiménez-Hernández, Luis Enrique; Torres, Alfredo G; Santos-Preciado, José Ignacio; Rosales-Reyes, Roberto.
Afiliación
  • Flores-Vega VR; Unidad de Investigación en Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City 06726, Mexico.
  • Monroy-Molina JV; Escuela de Ciencias de la Salud, Campus Coyoacán, Universidad del Valle de México, Calzada de Tlalpan 3000, Alcaldía Coyoacán, Mexico City 04910, Mexico.
  • Jiménez-Hernández LE; Unidad de Investigación en Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City 06726, Mexico.
  • Torres AG; Escuela de Ciencias de la Salud, Campus Coyoacán, Universidad del Valle de México, Calzada de Tlalpan 3000, Alcaldía Coyoacán, Mexico City 04910, Mexico.
  • Santos-Preciado JI; Escuela de Ciencias de la Salud, Campus Coyoacán, Universidad del Valle de México, Calzada de Tlalpan 3000, Alcaldía Coyoacán, Mexico City 04910, Mexico.
  • Rosales-Reyes R; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Viruses ; 14(4)2022 03 22.
Article en En | MEDLINE | ID: mdl-35458383
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent responsible for the coronavirus disease 2019 (COVID-19). The high rate of mutation of this virus is associated with a quick emergence of new viral variants that have been rapidly spreading worldwide. Several mutations have been documented in the receptor-binding domain (RBD) of the viral spike protein that increases the interaction between SARS-CoV-2 and its cellular receptor, the angiotensin-converting enzyme 2 (ACE2). Mutations in the spike can increase the viral spread rate, disease severity, and the ability of the virus to evade either the immune protective responses, monoclonal antibody treatments, or the efficacy of current licensed vaccines. This review aimed to highlight the functional virus classification used by the World Health Organization (WHO), Phylogenetic Assignment of Named Global Outbreak (PANGO), Global Initiative on Sharing All Influenza Data (GISAID), and Nextstrain, an open-source project to harness the scientific and public health potential of pathogen genome data, the chronological emergence of viral variants of concern (VOCs) and variants of interest (VOIs), the major findings related to the rate of spread, and the mutations in the spike protein that are involved in the evasion of the host immune responses elicited by prior SARS-CoV-2 infections and by the protection induced by vaccination.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Humans Idioma: En Revista: Viruses Año: 2022 Tipo del documento: Article País de afiliación: México Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Humans Idioma: En Revista: Viruses Año: 2022 Tipo del documento: Article País de afiliación: México Pais de publicación: Suiza